Novavax (NVAX) Q3 Revenue Surpasses Expectations at $70.45 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Yahoo Finance
- Revenue Beat: Novavax reported Q3 revenue of $70.45 million, a 16.6% year-over-year decline, yet it exceeded analyst expectations of $43.75 million, indicating some resilience in the market.
- Earnings Miss: The company posted an adjusted loss of $1.25 per share, which was worse than the expected loss of $1.13, reflecting ongoing pressure from high costs on profitability.
- Free Cash Flow Improvement: Free cash flow improved to $105.8 million from a negative $146.8 million in the same quarter last year, indicating progress in cash management.
- Cautious Market Outlook: Analysts project a 32.1% revenue decline over the next 12 months, suggesting that Novavax faces demand challenges that could impact its long-term growth potential.
Analyst Views on NVAX
Wall Street analysts forecast NVAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVAX is 11.25 USD with a low forecast of 6.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
4 Buy
1 Hold
3 Sell
Hold
Current: 6.720
Low
6.00
Averages
11.25
High
19.00
Current: 6.720
Low
6.00
Averages
11.25
High
19.00
About NVAX
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
